Sysmex Downgraded to Neutral From Buy at Citi
Citi analyst Hidemaru Yamaguchi downgraded Sysmex to Neutral from Buy with a 9,000 yen price target.
Sysmex Corporation GAAP EPS of ¥38.37, revenue of ¥86.03B
Sysmex Corporation press release (OTCPK:SSMXY): Q1 GAAP EPS of ¥38.37. Revenue of ¥86.03B (+8.0% Y/Y).
Sysmex Corporation GAAP EPS of ¥157.05, revenue of ¥258.9B
Sysmex Corporation press release (OTCPK:SSMXY): 9M GAAP EPS of ¥157.05.Revenue of ¥258.9B (+22.2% Y/Y).
Sysmex Corp Sees FY Net Y44.00B
Sysmex Corp. also released the following forecasts: GROUP Year Ending Mar 2022 Revenue Y360.00 bln Operating Profit Y66.00 bln Pretax Profit
Sysmex Corp 9-Mos Net Y32.90B Vs Net Y23.29B
Sysmex Corp. (6869.TO) Japan Nine Months Ended December 31 GROUP 2021 2020 Revenue Y258.90 bln Y211.85 bln Operating Profit Y49.87 bln
In-vitro Diagnostics Market to grow by USD 35.77 billion | Evolving Opportunities with Abbott Laboratories & Danaher Corp | 17000+ Technavio Reports
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The "In-vitro Diagnostics Market - Competitive Analysis, Drivers, Challenges, and Five Force Analysis" report has been added to Technavio's offering. The In-
10.32% CAGR in Chemiluminescence Immunoassay Analyzers Market | Increasing Prevalence of Acute and Chronic Diseases | Technavio
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The chemiluminescence immunoassay analyzers market size is anticipated to grow by USD 3.24 bn, progressing at a CAGR of 10.32%. This market forecast report pr
Sysmex downgraded to Neutral from Outperform at Daiwa
Daiwa analyst Tomoko Yoshihara downgraded Sysmex to Neutral from Outperform with a 15,300 yen price target.
In-vitro Diagnostics Instruments Market to Record a CAGR of 7.95% | Technavio
NEW YORK, Nov. 25, 2021 /PRNewswire/ -- The in-vitro diagnostics instruments market is expected to grow by USD 23.00 bn from 2020 to 2025, according to Technavio. The report offers an updated analys
Sysmex Corp 1H Net Y22.24B Vs Net Y12.65B
Sysmex Corp. (6869.TO) Japan 1st Half Ended September 30 GROUP 2021 2020 Revenue Y168.75 bln Y132.08 bln Operating Profit Y33.71 bln Y